Neurology · Episodic Ataxia Type 9

Treatment Options and Daily Management

At a Glance

EA9 treatment is individualized by the FGF14 genetic result. Acetazolamide may be tried for sequence variants, while 4-aminopyridine is used more often for related SCA27B; rehabilitation, activity, and tracking personal triggers can support balance.

Managing Episodic Ataxia Type 9 (EA9) and the related SCA27B focuses on two goals: reducing the frequency of sudden episodes and improving your baseline balance. Because these conditions are so rare, much of the treatment information is based on observational data—meaning what doctors have seen work in small groups of patients rather than large clinical trials ^[1]^[2].

Medication Options

There are two primary medications that doctors consider for FGF14-related conditions. The choice often depends on whether you have a sequence variant (EA9) or a repeat expansion (SCA27B). Do not start, stop, or change any medication without consulting your prescriber.

Acetazolamide

Traditionally used for other forms of episodic ataxia, acetazolamide is sometimes trialed for patients with FGF14 sequence variants.

How it works: It is a “carbonic anhydrase inhibitor” that helps stabilize the electrical environment around brain cells ^[3].
Evidence: In one case of an FGF14 variant, acetazolamide reduced attack frequency by about two-thirds ^[1]. While it is highly effective in other types of ataxia (like EA2), its effectiveness in EA9 specifically is still being studied ^[4].
Common Side Effects: Many patients experience a “tingling” sensation in their fingers and toes (paresthesia), a metallic taste when drinking carbonated beverages, or mild stomach upset. It can also cause metabolic acidosis, electrolyte abnormalities, kidney stones, and hypersensitivity reactions ^[3].

4-Aminopyridine (4-AP)

This medication is increasingly used for the repeat expansion form, SCA27B.

Evidence: Observational studies have reported that between 71% and 86% of patients with SCA27B feel an improvement in their balance or a reduction in “daily symptomatic time” when taking this medication ^[5]^[2]^[6].
Efficacy: Some patients report that their walking becomes steadier and their speech clearer, with benefits lasting for months ^[7]^[8].
Safety Note: 4-AP must be used with caution, as it can increase the risk of seizures in some people and requires monitoring of kidney function. Immediate-release compounded 4-AP is not interchangeable with extended-release dalfampridine ^[3].

Physical and Occupational Therapy

While medications treat the “electrical” side of the disease, therapy treats the “mechanical” side. Research into hereditary ataxias suggests that structured exercise is one of the most effective ways to maintain independence ^[9]^[10].

Intensive Rehab: Some evidence suggests that a 4-week intensive program—incorporating physical, occupational, and speech therapy—can lead to measurable short-term improvements in coordination and quality of life ^[11].
Targeted Training: Effective programs often focus on dynamic balance (staying steady while moving) and “locomotor programs” that teach the brain to better sense the body’s center of gravity ^[12]^[13].
Daily Activity: Even outside of a clinic, staying active through walking or balance exercises is recommended to help the brain compensate for the episodes ^[9]. However, unsupervised balance work can be dangerous; therapy should be paused during an active ataxia attack or unsafe illness.

Managing Triggers in Daily Life

Because attacks are often provoked by external stressors, “trigger avoidance” is a cornerstone of daily management. Patients have reported that the following can spark an episode:

Fever and Illness: Using over-the-counter medications can treat fever discomfort, though this does not necessarily prevent the ataxia ^[14]. Always seek medical assessment for significant illness.
Substances: Alcohol and caffeine are frequently cited as triggers. Some patients also find that cigarette smoking can worsen symptoms ^[15]^[16]^[17].
Physical and Emotional Stress: Intense exertion or sudden emotional shocks can push the nervous system toward an attack ^[15]^[18].

By keeping a “symptom diary,” you can identify which of these triggers apply to you specifically, allowing you to make lifestyle adjustments that give you more control over your condition.

Common questions in this guide

Which medication may be considered for episodic ataxia type 9?

When EA9 is linked to an FGF14 sequence variant, a clinician may trial acetazolamide, although its effectiveness for EA9 is still being studied. For the related SCA27B repeat-expansion condition, 4-aminopyridine is used more often; the genetic result helps guide the choice.

What side effects should I watch for with acetazolamide?

Common effects include tingling in the fingers or toes, a metallic taste with carbonated drinks, and mild stomach upset. Acetazolamide can also cause changes in the body's acid or electrolyte balance, kidney stones, or allergic reactions.

Does 4-aminopyridine help people with SCA27B?

Observational studies report that many people with SCA27B experience better balance or less time with symptoms while taking 4-aminopyridine. Responses vary, and treatment should include attention to seizure risk and kidney function.

Is immediate-release 4-aminopyridine the same as extended-release dalfampridine?

No. Immediate-release compounded 4-aminopyridine is not interchangeable with extended-release dalfampridine, and the prescribed formulation should be used exactly as directed. 4-aminopyridine can increase seizure risk and requires attention to kidney function.

Can rehabilitation help with EA9 balance problems?

Structured physical, occupational, and speech therapy may improve coordination and quality of life in the short term, while balance and walking programs can help maintain independence. Exercises should be individualized and supervised when needed, and paused during an active attack or unsafe illness.

How can I identify and avoid my episodic ataxia triggers?

Reported triggers include fever or illness, alcohol, caffeine, cigarette smoking, intense exertion, and sudden emotional stress. A symptom diary can help identify your personal triggers and guide daily adjustments, but significant illness still needs medical assessment.

Get notified when new evidence is published on episodic ataxia, type 9.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

References (18)

1
Acetazolamide-Responsive Episodic Ataxia Linked to Novel Splice Site Variant in FGF14 Gene.
Schesny M, Joncourt F, Tarnutzer AA
Cerebellum (London, England) 2019; (18(3)):649-653 doi:10.1007/s12311-018-0997-3.
PMID: 30607796
2
Spinocerebellar Ataxia Type 27B can be Suspected Based on Clinical Phenotype: The Massachusetts General Hospital Ataxia Center Experience.
Rettenmaier LA, Chen JYH, MacMore J, et al.
Cerebellum (London, England) 2025; (24(5)):133 doi:10.1007/s12311-025-01882-3.
PMID: 40679574
3
Fampridine and Acetazolamide in EA2 and Related Familial EA: A Prospective Randomized Placebo-Controlled Trial.
Muth C, Teufel J, Schöls L, et al.
Neurology. Clinical practice 2021; (11(4)):e438-e446 doi:10.1212/CPJ.0000000000001017.
PMID: 34484942
4
Episodic Ataxias: Primary and Secondary Etiologies, Treatment, and Classification Approaches.
Hassan A
Tremor and other hyperkinetic movements (New York, N.Y.) 2023; (13()):9 doi:10.5334/tohm.747.
PMID: 37008993
5
GAA-FGF14 ataxia (SCA27B): phenotypic profile, natural history progression and 4-aminopyridine treatment response.
Wilke C, Pellerin D, Mengel D, et al.
Brain : a journal of neurology 2023; (146(10)):4144-4157 doi:10.1093/brain/awad157.
PMID: 37165652
6
Clinical, Radiological and Pathological Features of a Large American Cohort of Spinocerebellar Ataxia (SCA27B).
Abou Chaar W, Eranki AN, Stevens HA, et al.
Annals of neurology 2024; (96(6)):1092-1103 doi:10.1002/ana.27060.
PMID: 39263992
7
Downbeat Nystagmus and Saccadic Oscillations in Spinocerebellar Ataxia Type 27B: A 14-Month Follow-Up Case Report.
Skacik P, Koprusakova MT, Sivak S, et al.
Case reports in neurology 2026; (18(1)):436-441 doi:10.1159/000552966.
PMID: 42569714
8
Video-Oculography as a Key Diagnostic Tool for SCA27B: A Real-Life Experience.
Coulette S, Lecler A, Le Cossec C, et al.
European journal of neurology 2025; (32(6)):e70228 doi:10.1111/ene.70228.
PMID: 40556471
9
Goal-Directed Rehabilitation Versus Standard Care for Individuals with Hereditary Cerebellar Ataxia: A Multicenter, Single-Blind, Randomized Controlled Superiority Trial.
Milne SC, Roberts M, Williams S, et al.
Annals of neurology 2025; (97(3)):409-424 doi:10.1002/ana.27130.
PMID: 39520242
10
Effects of physiotherapy on degenerative cerebellar ataxia: a systematic review and meta-analysis.
Matsugi A, Bando K, Kondo Y, et al.
Frontiers in neurology 2024; (15()):1491142 doi:10.3389/fneur.2024.1491142.
PMID: 39866519
11
Amelioration of motor and nonmotor symptoms in cortical cerebellar atrophy and multiple system atrophy-cerebellar type by inpatient rehabilitation: a retrospective study.
Sonoda Y, Yamanaka Y, Sawano S, et al.
International journal of rehabilitation research. Internationale Zeitschrift fur Rehabilitationsforschung. Revue internationale de recherches de readaptation 2021; (44(2)):104-109 doi:10.1097/MRR.0000000000000455.
PMID: 33481455
12
The effect of a task-specific locomotor training strategy on gait stability in patients with cerebellar disease: a feasibility study.
Im SJ, Kim YH, Kim KH, et al.
Disability and rehabilitation 2017; (39(10)):1002-1008 doi:10.1080/09638288.2016.1177124.
PMID: 27216372
13
Effectiveness and cost of integrated cognitive and balance training for balance and falls in cerebellar ataxia: a blinded two-arm parallel group RCT.
Winser SJ, Chan AYY, Whitney SL, et al.
Frontiers in neurology 2023; (14()):1267099 doi:10.3389/fneur.2023.1267099.
PMID: 38313407
14
FGF14-related episodic ataxia: delineating the phenotype of Episodic Ataxia type 9.
Piarroux J, Riant F, Humbertclaude V, et al.
Annals of clinical and translational neurology 2020; (7(4)):565-572 doi:10.1002/acn3.51005.
PMID: 32162847
15
Paroxysmal Ataxia: A Characteristic Feature of FGF14 Repeat Expansion (SCA27B).
Foucard C, Belley M, Sangare A, et al.
Neurology. Genetics 2024; (10(1)):e200118 doi:10.1212/NXG.0000000000200118.
PMID: 38170134
16
Spinocerebellar Ataxia Type 27B (SCA27B): A Hereditary Ataxia in Portugal.
Mendes Ferreira V, Magriço M, Meira B, Barbosa R
Acta medica portuguesa 2025; (38(6-7)):408-411 doi:10.20344/amp.22232.
PMID: 39392764
17
How to distinguish spinocerebellar ataxia 27B from late onset cerebellar ataxia: insights from a case-control study.
Pinheiro-Barbosa R, Cissé C, Bastos P, et al.
Journal of neurology 2024; (272(1)):45 doi:10.1007/s00415-024-12738-x.
PMID: 39666053
18
Episodic ataxia type 2 (EA2) with interictal myokymia and focal dystonia.
Nielsen EN, Ásbjörnsdóttir B, Møller LB, et al.
Cold Spring Harbor molecular case studies 2022; (8(6)) doi:10.1101/mcs.a006236.
PMID: 36307210

This page is for informational purposes only and does not constitute medical advice about EA9. Your neurologist, prescriber, and rehabilitation team should tailor medication, therapy, and safety monitoring to your genetic result and health.